Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA2 | P47869 | 4/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.46 |
| ▸ | MIF | P14174 | 1/20 | 0.45 |
| ▸ | DDX3X | O00571 | 6/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | RXRA | P19793 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17978588 | 0.79 | ALDH1A1 (0.43) | GABRA2GABRB2MIFDDX3XNOTUM | |
| SCHEMBL17978544 | 0.77 | MIF (0.67) | GABRA2GABRB2MIFDDX3XNOTUM | |
| SCHEMBL4020226 | 0.76 | LRRK2 (0.46) | NOTUMRXRAGRIN1GRIN2B | |
| SCHEMBL13939916 | 0.72 | ALDH1A1 (0.36) | NOTUMRXRAGRIN1GRIN2B | |
| SCHEMBL28309985 | 0.70 | MIF (0.49) | GABRA2GABRB2MIFDDX3XNOTUM | |
| SCHEMBL19232418 | 0.69 | NOTUM (0.52) | NOTUML3MBTL1RXRAGRIN1GRIN2B | |
| SCHEMBL12395785 | 0.67 | JAK2 (0.43) | GABRA2GABRB2MIFNOTUMKCNH2 | |
| SCHEMBL17978520 | 0.67 | DDX3X (0.52) | MIFDDX3XKCNH2 | |
| SCHEMBL17978602 | 0.66 | MIF (0.51) | MIFNOTUM | |
| SCHEMBL21974268 | 0.66 | RXRA (0.59) | MIFDDX3XRXRAGRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3256461-B1 | UREA AND SULFONAMIDE DERIVATIVES AS HUMAN HELICASE DDX3 INHIBITORS USEFUL IN THE TREATMENT OF VIRAL DISEASES | AZIENDA OSPEDALIERA UNIV SENESE (IT) | 2023-09-13 | — | — | EP | disclosed |
| EP-3432881-B1 | USE OF DDX3 INHIBITORS AS ANTIPROLIFERATIVE AGENTS | AZIENDA OSPEDALIERA UNIV SENESE (IT) | 2021-11-24 | — | — | EP | disclosed |
| US-11000512-B2 | Use of DDX3 inhibitors as antiproliferative agents | AZIENDA OSPEDALIERA UNIVERSITARIA SENESE (IT) | 2021-05-11 | — | — | US | disclosed |
| US-10941121-B2 | Human helicase DDX3 inhibitors as therapeutic agents | AZIENDA OSPEDALIERA UNIVERSITARIA SENESE (IT) | 2021-03-09 | — | — | US | disclosed |
| US-20200140398-A1 | HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS | AZIENDA OSPEDALIERA UNIVERSITARIA SENESE (IT) | 2020-05-07 | — | — | US | disclosed |
| US-20190099403-A1 | USE OF DDX3 INHIBITORS AS ANTIPROLIFERATIVE AGENTS | AZIENDA OSPEDALIERA UNIVERSITARIA SENRESE (IT) | 2019-04-04 | — | — | US | disclosed |
| EP-3432881-A1 | USE OF DDX3 INHIBITORS AS ANTIPROLIFERATIVE AGENTS | Azienda Ospedaliera Universitaria Senese (IT) | 2019-01-30 | — | — | EP | disclosed |
| CN-109069484-A | Purposes of the DDX3 inhibitor as antiproliferative | 锡耶纳大学医院 | 2018-12-21 | — | — | CN | disclosed |
| US-20180016243-A1 | HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS | AZIENDA OSPEDALIERA UNIVERSITARIA SENESE (IT) | 2018-01-18 | — | — | US | disclosed |
| EP-3256461-A1 | HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS | Azienda Ospedaliera Universitaria Senese (IT) | 2017-12-20 | — | — | EP | disclosed |
| WO-2017162834-A1 | USE OF DDX3 INHIBITORS AS ANTIPROLIFERATIVE AGENTS | AZIENDA OSPEDALIERA UNIVERSITARIA SENESE (IT) | 2017-09-28 | — | — | WO | disclosed |
| WO-2016128541-A1 | HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS | AZIENDA OSPEDALIERA UNIVERSITARIA SENESE (IT) | 2016-08-18 | — | — | WO | disclosed |
| WO-2016128541-A1 | HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS | AZIENDA OSPEDALIERA UNIVERSITARIA SENESE (IT) | 2016-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11000512-B2 | Use of DDX3 inhibitors as antiproliferative agents | DDX3X, DDX21, DDB1 | GABRA2 4270/4885GABRB2 3281/4885MIF 678/4885 |
| US-20180016243-A1 | HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS | DDX3X, DDX39B, DDX1 | GABRA2 4414/4885GABRB2 3895/4885MIF 943/4885 |
| US-20200140398-A1 | HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS | DDX3X, DDX39B, DDX1 | GABRA2 4414/4885GABRB2 3895/4885MIF 943/4885 |
| US-10941121-B2 | Human helicase DDX3 inhibitors as therapeutic agents | DDX3X, DDX39B, DDX1 | GABRA2 4414/4885GABRB2 3895/4885MIF 943/4885 |
| US-20190099403-A1 | USE OF DDX3 INHIBITORS AS ANTIPROLIFERATIVE AGENTS | DDX21, DDX3X, DDB1 | GABRA2 4302/4885GABRB2 3252/4885MIF 617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.